Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Myeloma is one of the interleukin (IL)-6-related diseases to which abnormal expression of IL-6 has been reported to be linked. We examined the in vivo inhibitory effect of anti-human IL-6 receptor (IL-6R) antibody on human myeloma cell growth in mice. SCID mice were subcutaneously inoculated with solid tumor of the myeloma cell line S6B45 in which human IL-6 was acting as an autocrine growth factor. Ten intraperitoneal administrations of 100 micrograms of the anti-human IL-6R antibody PM1 at 48-h intervals strongly inhibited the growth of S6B45 cells when the administration started 24 h after tumor inoculation. The tumor growth inhibition in vivo was also observed by administration of the anti-human IL-6 antibody MH166 using the same procedure as for PM1. The inhibitory effect of PM1 was not significant when the administration started 5 or more days after tumor inoculation. This work indicates that anti-human IL-6R antibody, as well as anti-human IL-6 antibody inhibits human myeloma growth in vivo, and provides an animal model for testing the therapeutic value of agents such as antibodies to human IL-6, IL-6R and gp130, an IL-6R-associated signal transducer, in the treatment of human myelomas.
Suzuki
H
H
Biotechnology Research Laboratory, Tosoh Corporation, Kanagawa, Japan.
Yasukawa
K
K
Saito
T
T
Goitsuka
R
R
Hasegawa
A
A
Ohsugi
Y
Y
Taga
T
T
Kishimoto
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D051379:Mice; D016513:Mice, SCID; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy*; D011971:Receptors, Immunologic / Q000032:analysis / Q000276:immunology*; D019947:Receptors, Interleukin-6; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D011971:Receptors, Immunologic; D019947:Receptors, Interleukin-6